| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sulfasalazine is primarily known as an anti-inflammatory and disease‐modifying antirheumatic drug (DMARD), used for conditions such as rheumatoid arthritis and inflammatory bowel diseases (e.g., ulcerative colitis). -Inhibit the nuclear factor kappa B (NF-κB) pathway. -Sulfasalazine has been noted to interfere with the cystine/glutamate antiporter (system x_c⁻), which can reduce glutathione levels in cancer cells, potentially making them more susceptible to oxidative stress. -Ability to inhibit anti-oxidant production (for ProOxidant effect).
|
| Source: |
| Type: |
| Glutamine is an amino acid that fuels various metabolic pathways, supporting bioenergetics, biosynthesis, and redox balance in cancer cells. -Many breast tumors exhibit glutamine addiction, relying on enhanced glutamine uptake and metabolism to support rapid proliferation. -In many tumor types—such as breast, lung, colorectal, liver, and pancreatic cancers—enhanced glutamine metabolism is often associated with a more aggressive phenotype, therapy resistance, and poorer patient outcomes. |
| 5037- | SAS, | Inhibition of xCT by sulfasalazine alleviates the depression-like behavior of adult male mice subjected to maternal separation stress |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:286 Target#:1244 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid